BioPharmSignal logoBioPharmSignal

Biotech News

Adlai Nortye Reports Full Year 2024 Financial Results and Business Updates

Adlai Nortye Ltd. (ANL)Adlai Nortye Ltd.Earnings

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, April. 30, 2025 -- Adlai Nortye Ltd. (NASDAQ: ANL) (the "Company" or "Adlai Nortye"), a global clinical-stage biotechnology company focused on the development of innovative targeted and immune-modulating cancer therapies, today announced its

Related news

ANLAdlai Nortye Ltd.2026-08-14 11:00 EST

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

GNLXGenelux2026-08-13 20:20 EST

Genelux Corporation Reports Second Quarter Financial Results and Provides Business Updates

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

MMSIMerit Medical2026-07-30 20:05 EST

Merit Medical Reports Second Quarter 2026 Results And Updates Full-Year 2026 Guidance

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

SNDXSyndax Pharmaceuticals2026-07-28 11:00 EST

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

REPLReplimune Group2026-06-29 12:00 EST

Replimune Reports Fiscal Fourth Quarter and Year End 2026 Financial Results and Provides Corporate Update

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

Adlai Nortye Ltd.

Annovis Bio is a biotechnology company focused on neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Its story centers on trying to address difficult CNS diseases with a focused molecular approach.

Recent company news

ANLAdlai Nortye Ltd.2026-08-14 11:00 EST

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

ANLAdlai Nortye Ltd.2026-08-03 11:00 EST

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

ANLAdlai Nortye Ltd.2026-07-16 11:00 EST

Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025

ANLAdlai Nortye Ltd.2026-07-13 11:00 EST

Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists

ANLAdlai Nortye Ltd.2026-04-16 10:59 EST

Adlai Nortye Announces $150.0 Million Private Placement Equity Financing

Stock data

Close
13.70 USD
Market cap
745.73M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States